Print this page
-
An Open-Label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Protocol: 052011Principal Investigator:
- Missak Haigentz MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Breast
Esophagus
Lung -
A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Cancers of the Stomach, Breast, Lung and Cervix.
Protocol: 192004Principal Investigator:
- Christian Hinrichs (Rutgers University)
Applicable Disease Sites: Any Site
Stomach
Breast
Lung
Cervix -
I-SPY 2 TRIAL: (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).
Protocol: 042102Principal Investigator:
- Coral Omene MD, PhD (Rutgers University)
Applicable Disease Sites: Breast -
A Phase II Study of U3-1402 in Patients with Metastatic Breast Cancer.
Protocol: 042103Principal Investigator:
- Deborah Toppmeyer M.D. (Rutgers University)
Applicable Disease Sites: Breast -
A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib.
Protocol: 042106Principal Investigator:
- Coral Omene MD, PhD (Rutgers University)
Applicable Disease Sites: Breast -
GS-US-592-6238-A Randomized, Open-Label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1.
Protocol: 042202Principal Investigator:
- Coral Omene MD, PhD (Rutgers University)
Applicable Disease Sites: Breast